Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX43 + HLX10 + HLX07
- Development stage
- Phase 2
- Lead developer
- Henlius
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX43 + HLX10 + HLX07 is a combination therapy developed by Shanghai Henlius Biotech for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The regimen consists of HLX43, a potential best-in-class antibody-drug conjugate (ADC) targeting PD-L1; HLX10 (serplulimab), a humanized monoclonal antibody targeting the PD-1 immune checkpoint; and HLX07, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR). HLX43 utilizes MediLink Therapeutics' TMALIN® technology to conjugate a topoisomerase I inhibitor payload to an anti-PD-L1 antibody with a drug-antibody ratio (DAR) of 8. This triple combination aims to leverage the synergistic effects of immune checkpoint blockade (PD-1/PD-L1) and EGFR inhibition alongside payload-mediated cytotoxicity to overcome resistance and improve outcomes in HNSCC.
- Other names
- HLX43 + serplulimab + HLX07
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HLX43 + HLX10 + HLX07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX43 + HLX10 + HLX07.